DEVELOPMENTAL RESEARCH PROGRAM

发展研究计划

• 批准号: 8997370
• 负责人: ANAS YOUNES
• 金额: $ 22.43万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-30 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8997370
• 关键词: Academic Medical Centers; Adult; Award; Budgets; Clinical; Collaborations; Development; Diagnosis; Female; Funding; Goals; Grant; Herbert Irving Comprehensive Cancer Center; Individual; Institution; Lymphoma; Memorial Sloan-Kettering Cancer Center; Monitor; Non-Hodgkin' s Lymphoma; Patients; Peer Review; Physicians; Pilot Projects; Procedures; Process; Recruitment Activity; Reproduction spores; Request for Proposals; Research; Research Infrastructure; Research Personnel; Research Project Grants; Scientist; Seeds; Testing; Translational Research; Underrepresented Minority; United States National Institutes of Health; base; cancer type; high risk; improved; medical schools; novel; programs

DRP Director: John Leonard, MD (WCMC) Co-Director: Anas Younes (MSK) DRP SUMMARY The Developmental Research Program (DRP) will identify new opportunities to support physicians and scientists, and encourage them to use their expertise to develop novel translational research ideas in lymphoma. The DRP will provide seed funding to generate and explore new hypotheses that may subsequently be expanded and tested as full project within the Lymphoma SPORE, or through other SPORE- independent peer-reviewed external grant support. The purpose of the SPORE DRP is to develop translational research projects that should result in testable hypotheses aimed at improving the diagnosis and treatment of lymphoma. On an annual basis, a request for proposals will be distributed to all participating institutions. Selected proposals (1-2 annually) will be supported with $50,000 of the SPORE budget with matching institutional support. Funding will be awarded for 1 year. Based on accomplishments during the first year, and review by the EAB, funding may be extended by a second year. Usual NIH review criteria will be used in selection of projects. Proposals from underrepresented minority and female applicants will be specifically solicited. The program takes advantage of a strong group of investigators with documented scientific record and outstanding infrastructure at all three participating Institutions, Memorial Sloan Kettering Cancer Center (MSK), Weill-Cornell Medical College (WCMC) and the Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center.

drp 主任：医学博士John Leonard（WCMC） 联合导演：Anas Younes（MSK） DRP摘要 发展研究计划（DRP）将确定支持医生和 科学家，并鼓励他们利用自己的专业知识来发展新颖的翻译研究思想 淋巴瘤。 DRP将提供种子资金，以产生和探索可能 随后在淋巴瘤孢子中或通过其他孢子 - 独立的同行评审外部赠款支持。孢子DRP的目的是发展翻译 研究项目应导致可检验的假设，旨在改善诊断和治疗 淋巴瘤。每年，提案请求将分发给所有参与机构。 选定的提案（每年1-2）将得到$ 50,000的孢子预算的支持 机构支持。资金将授予1年。基于第一年的成就，以及 EAB的审查，资金可以延长第二年。常规的NIH审查标准将用于 选择项目。代表性不足的少数民族和女性申请人的建议将是专门的 征求。该计划利用有记录的科学记录的强大调查人员 以及所有三个参与机构的杰出基础设施 （MSK），Weill-Cornell医学院（WCMC）和哥伦比亚大学医学中心/Herbert Irving 综合癌症中心。